Mark P. Famiglio
Chief Executive Officer

Mark P. Famiglio is the CEO and Co-Founder of Cambryn. Mr. Famiglio is a seasoned entrepreneur with strategic, operational and management experience across several industries. Mr. Famiglio co-founded Copytalk, a voice-to-text documentation service, Proscript Documentation Services, a U.S. hospital documentation service provider, and Boston Information Technology. He is currently a Director of Copytalk. He previously served in leadership roles at both Proscript and Boston Information Technology prior to selling both businesses. Mr. Famiglio also manages Aviation Partners of America, where he is a Co-Founder and Owner. He began his career in commercial real estate where he has a successful long-standing track record as a builder and financer of various projects.

Mr. Famiglio has had board leadership positions in and is a recognized supporter of various cultural and non-profit corporations, including: United Cerebral Palsy, Florida State University College of Medicine, WUSF public television, Ringling Museum of Art, Sarasota Ballet, Sarasota Opera, Sarasota Film Festival, Manatee Economic Development Council, Nantucket Film Festival and the Van Wezel Performing Arts Hall Foundation.

Mr. Famiglio's business experience, including his senior executive roles at multiple companies, his experience as an investor, his service on committees of academic institutions and other company boards, combined with his business acumen and judgment, provide Cambryn with valuable strategic and operational expertise and leadership skills.


Marc Paquin
Chief Operating Officer

Mr. Paquin joined Cambryn Biologics in January 2012. From 1989 to 2007, he was founder, and CEO of Haemacure Corporation, where he conceptualized the development of a plasma fractionation process to separate fibrinogen and thrombin as a Fibrin Sealant product. During his tenure with Haemacure, he was involved in several partnerships and licensing agreements with the Swiss Red Cross, US-Federal Trade Commission and Bio Product Laboratory, U.K. the biological manufacturing arm of the British Government. In 1996, he lead the initial public offering for the company. In 1986, he founded Autologous Systems, Inc., the first Canadian commercial private blood bank and developed a process to freeze red cells, and originated the concept for fibrin sealant. His career started with the initial set-up of SYVA - Syntex Biomedical Division (Canada) in enzyme-immunology technology and became Vice-President and General Manager. Mr. Paquin's background is in Health Sciences and Management from McGill University. He has developed patents relating to fibrin sealant and other biomaterials.


Valli Baldassano

Valli Baldassano is an attorney with extensive experience in the pharmaceutical industry. Prior to joining Cambryn Biologics, she was the Executive Vice President and Chief Compliance Officer of Cephalon, Inc., where she was responsible for Cephalon’s Global Compliance program and the Worldwide Quality Assurance team. Ms. Baldassano has extensive experience in the design and implementation of compliance and quality programs for multinational corporations. She served as Vice President of Global Compliance for Schering-Plough’s Global Prescription Business and Global Specialty Operations and was a Senior Director of Global Compliance for Pharmacia Corporation. Prior to joining the pharmaceutical industry, she spent 8 years as an Assistant United States Attorney for the Criminal Division of the United States Attorney’s Office for the Eastern District of Pennsylvania, where she prosecuted federal crimes relating to healthcare fraud, public corruption, insurance fraud and serious narcotics trafficking. Ms. Baldassano graduated from Georgetown University and earned a law degree from Syracuse University.


Joseph Buettner
Director of Process Development and R&D

Mr. Joseph Buettner is Director of Process Development and R&D. Mr. Buettner has over 27 years of experience in Research & Development of Biopharmaceuticals. He was formerly with Bayer’s Bio-sciences for 11 years, where he supervised an R & D group. Mr. Buettner holds a master in microbiology and has done advanced studies in Biochemistry.





Irlande Elie
Director of Quality Assurance/Quality Control

Ms. Irlande Elie is Director of Quality Assurance/Quality Control. In her present role, she has responsibility for the company’s Quality Management System and compliance with cGMP requirements as mandated by the Food and Drug Administration (FDA). Ms. Elie has more than fifteen years of pharmaceutical industry experience in quality assurance, quality control, and research and development. Prior to joining Cambryn Biologics, she worked in research and development and quality for MiMedx Group, in quality assurance for start-up company Haemacure Corporation and as a quality control analyst for R.P. Scherer, an early-stage predecessor to Catalent Pharma Solutions. Ms. Elie holds a Bachelors degree in Chemistry from the University of South Florida.

Cambryn Biologics LLC

Cambryn Biologics LLC is a Delaware corporation having its principal facility and offices in Sarasota, Florida. Cambryn is an emerging biotherapeutic company dedicated to the development, manufacturing and commercialization of biologic products for the management and treatment of clotting factor deficiencies.

logo small

State-of-the-Art Manufacturing Facility

Our facility consists of 50,000 square feet, located adjacent to the Sarasota/Bradenton International Airport, Sarasota, Florida, USA. Cambryn Biologics operates a state-of-the-art manufacturing facility.

Contact Details

Address: 600 Tallevast Rd.
Suite 201 Sarasota, FL 34243

Phone: (941) 355-7400

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.